Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Assertio Holdings, Inc.NASDAQ: ASRT

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $9.93M fell 62.5% year over year, behind the -14.2% change in trailing-twelve-month revenue. Sequentially, it fell 26.7% from the prior quarter. Over 3 fiscal years it compounded at -8.7% a year.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $105.86M (-10.8%) for the fiscal year ending Dec 2026, a slowdown from the -5.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.93M-26.7% QoQ
Last fiscal yearDec 2025
$118.71M-5.0% YoY
LTMMar 2026
$102.16M-14.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-62.5%-5.3%+57.2 pp
1 year-5.0%-10.8%-5.8 pp
3-year CAGR-8.7%-4.7%+4.1 pp
5-year CAGR+0.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
118.71M USD
Year-over-year change
-5.0%
4-year CAGR
+1.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -14.2% is the 6th highest of 7, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of -8.7% compares with a peer median of -3.3%.
ASRT Competitors
Revenue for ASRT and competitors
Company Period LTM YoY 3-year CAGR
VXRTVaxart, Inc.LTM Mar 2026$255.61M USD+439.3%+1204.0%
INCRInterCure Ltd.LTM Jun 2025₪243.12M ILS-10.8%-11.4%
ASRTAssertio Holdings, Inc.LTM Mar 2026$102.16M USD-14.2%-8.7%
LUNGPulmonx CorporationLTM Mar 2026$88.55M USD+1.2%+19.0%
FBIOFortress Biotech, Inc.LTM Mar 2026$66.16M USD+14.5%-5.8%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$9.14M USD+106.7%-8.6%
NTRBNutriband Inc.LTM Apr 2026$1.8M USD-24.8%-0.7%
XBITXBiotech Inc.LTM Mar 2026$0 USD——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 USD——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 USD——
Peer median (excluding ASRT) —+7.9%-3.3%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue111.01M156.23M152.07M124.96M118.71M
Cost of Revenue15.83M18.75M27.02M39.23M65.39M
Gross Profit95.18M137.49M125.05M85.73M53.33M
Gross Margin85.7%88.0%82.2%68.6%44.9%
Research & Development002.84M3.82M1.69M
Selling, General & Admin56.56M48.1M69.74M76.95M68.86M
Operating Expenses85.76M98.08M368.59M110.21M70.55M
Depreciation & Amortization29.11M33.4M28.23M25.83M30.01M
EBITDA38.78M90.17M53.17M5.15M3.14M
EBITDA Margin34.9%57.7%35.0%4.1%2.6%
Operating Income9.42M39.41M(243.54M)(24.48M)(17.22M)
Operating Margin8.5%25.2%-160.1%-19.6%-14.5%
Interest Income0003.22M2.67M
Interest Expense10.22M7.96M3.38M3.04M3.08M
Other Income / Expenses(9.98M)(8.24M)(10.52M)2.95M(12.72M)
Income Before Tax(553K)31.17M(254.05M)(21.53M)(29.94M)
Pre-Tax Margin-0.5%19.9%-167.1%-17.2%-25.2%
Income Tax Expense728K(78.46M)77.89M52K435K
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Net Margin-1.2%70.2%-218.3%-17.3%-25.6%
EPS (Basic)(0.45)34.95(70.05)(3.45)(4.74)
EPS (Diluted)(0.45)30.45(70.05)(3.45)(4.74)
Weighted Avg Shares2.88M3.13M4.74M6.35M6.4M
Weighted Avg Shares (Diluted)2.88M3.64M4.74M6.35M6.4M

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.